Cellusion raises additional funding and welcomes a new board member


TOKYO (May 31, 2020)-, Cellusion Inc. (Headquarters, Tokyo; CEO: Shin Hatou, M.D., Ph.D., “Cellusion”) announced 110M JPY an additional Series A funding raising from Industrial Technology Investment Corporation (Headquarters, Taipei; CEO: Yi-Chih (Hans) Tai, “ITIC”) and others. With this fundraising, Cellusion is preparing to conduct clinical study for obtaining first in human data and to start global development. Along with this fundraising, Cellusion welcomes Hans Tsai from ITIC as our new board member. Hans is known as a successful investor in Silicon Valley and has rich experiences on startups and corporate managements including Sunplus Technology Co., Ltd. and ITIC. Cellusion will accelerate to develop novel regenerative therapy for all bullous keratopathy patients in the world.

For further information: please ask us through contact form in our website.

<About Industrial Technology Investment Corporation>
ITIC is a venture capital firm operating out of Taiwan. Since our founding in 1979, ITIC invested over 400MUSD across the globe to nurture industry leaders. ITIC has unique value proposition to startups and partners stems from two key strengths: the depth of expertise drawing on, and the breadth of resources drawing from.
Company : Industrial Technology Investment Corporation
CEO :Yi-Chih (Hans) Tai
Headquarters :6F., No.106, Sec. 2, Heping E. Rd., Da’an Dist., Taipei City 106, Taiwan (R.O.C.)
Founded : 1979

<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Company : Cellusion Inc.
CEO : Shin Hatou, M.D., Ph.D.
Headquarters :1-13-7 Nihombashi-Muromachi, Chuo, Tokyo 103-0022, JAPAN
Founded : January 2015

Back to the List